Skip to main content
Erschienen in: Der Gynäkologe 5/2016

01.05.2016 | Review

Endocrine interventions in women with BRCA1/2 mutations

A systematic review

verfasst von: Dr. Susanne Schüler-Toprak, PD Dr. Stephan Seitz, Prof. Dr. Olaf Ortmann

Erschienen in: Die Gynäkologie | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

One in eight women will be diagnosed with breast cancer and 5 % of all breast cancer cases are attributable to a mutation in BRCA1 or BRCA2. Lifetime risk of the general population is about 1.5 %. The probability of an underlying mutation depends on family history, histologic subtype and age at diagnosis. For healthy BRCA1/2 mutation carriers, ovarian cancer risk varies between 15 and 60 % depending of the mutation and modifying factors.

Objectives

The safety of endocrine interventions in BRCA1/2 mutation carriers has been investigated in numerous trials. In this article an update on the current knowledge on safety of oral contraception, hormone therapy and fertility treatment in BRCA1/2 mutation carriers is provided. Furthermore, options for primary prevention are discussed.

Materials and methods

A systematic search in the Medline literature database through PubMed using the terms “BRCA”, “famil*”, “breast cancer”, “ovarian cancer”, “oral contraception”, “fertility”, “fertility treatment”, “infertility”, “tamoxifen”, “raloxifene”, “chemoprevention”, “prevention”, “hormone”, “hormone treatment”, “hormone therapy”, “salpingo-oophorectomy” and “endocrine” was performed. Articles published between 1995 and 2015 were included.

Conclusions

Oral contraceptives seem to slightly increase the breast cancer risk of BRCA1/2 mutation carriers, but they also have a tremendous protective effect against ovarian cancer. Parity, breastfeeding and fertility treatment do not seem to influence cancer risk in these women. Hormone therapy should be offered after risk-reducing salpingo-oophorectomy to limit osteoporosis and cardiac mortality. Tamoxifen and raloxifene are effective for primary prevention of breast cancer in BRCA1/2 mutation carriers; however possible adverse effects must be considered.
Literatur
1.
Zurück zum Zitat Anonymous (2002) Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med 137:56–58CrossRef Anonymous (2002) Chemoprevention of breast cancer: recommendations and rationale. Ann Intern Med 137:56–58CrossRef
2.
Zurück zum Zitat Antoniou AC, Rookus M, Andrieu N et al (2009) Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 18:601–610PubMedCrossRef Antoniou AC, Rookus M, Andrieu N et al (2009) Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev 18:601–610PubMedCrossRef
3.
Zurück zum Zitat Armstrong K, Schwartz JS, Randall T et al (2004) Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 22:1045–1054PubMedCrossRef Armstrong K, Schwartz JS, Randall T et al (2004) Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 22:1045–1054PubMedCrossRef
4.
Zurück zum Zitat Becker C (2010) Another selective estrogen-receptor modulator for osteoporosis. N Engl J Med 362:752–754PubMedCrossRef Becker C (2010) Another selective estrogen-receptor modulator for osteoporosis. N Engl J Med 362:752–754PubMedCrossRef
5.
Zurück zum Zitat Beral V, Bull D, Green J et al (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369:1703–1710PubMedCrossRef Beral V, Bull D, Green J et al (2007) Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 369:1703–1710PubMedCrossRef
6.
Zurück zum Zitat Beral V, Gaitskell K, Hermon C et al (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835–1842PubMedCrossRef Beral V, Gaitskell K, Hermon C et al (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835–1842PubMedCrossRef
7.
Zurück zum Zitat Bonanni B, Lazzeroni M (2013) Acceptability of chemoprevention trials in high-risk subjects. Ann Oncol 24(Suppl 8):viii42–viii46PubMedCrossRef Bonanni B, Lazzeroni M (2013) Acceptability of chemoprevention trials in high-risk subjects. Ann Oncol 24(Suppl 8):viii42–viii46PubMedCrossRef
8.
Zurück zum Zitat Braithwaite RS, Chlebowski RT, Lau J et al (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937–947PubMedPubMedCentralCrossRef Braithwaite RS, Chlebowski RT, Lau J et al (2003) Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18:937–947PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Brohet RM, Goldgar DE, Easton DF et al (2007) Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 25:3831–3836PubMedCrossRef Brohet RM, Goldgar DE, Easton DF et al (2007) Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. J Clin Oncol 25:3831–3836PubMedCrossRef
10.
Zurück zum Zitat Challberg J, Ashcroft L, Lalloo F et al (2011) Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 105:22–27PubMedPubMedCentralCrossRef Challberg J, Ashcroft L, Lalloo F et al (2011) Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 105:22–27PubMedPubMedCentralCrossRef
11.
Zurück zum Zitat Cibula D, Gompel A, Mueck AO et al (2010) Hormonal contraception and risk of cancer. Hum Reprod Update 16:631–650PubMedCrossRef Cibula D, Gompel A, Mueck AO et al (2010) Hormonal contraception and risk of cancer. Hum Reprod Update 16:631–650PubMedCrossRef
12.
Zurück zum Zitat Cibula D, Zikan M, Dusek L et al (2011) Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 11:1197–1207PubMedCrossRef Cibula D, Zikan M, Dusek L et al (2011) Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Rev Anticancer Ther 11:1197–1207PubMedCrossRef
13.
Zurück zum Zitat Collaborative Group on Epidemiolo (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314CrossRef Collaborative Group on Epidemiolo (2008) Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 371:303–314CrossRef
14.
Zurück zum Zitat Cullinane CA, Lubinski J, Neuhausen SL et al (2005) Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. J Int Cancer 117:988–991CrossRef Cullinane CA, Lubinski J, Neuhausen SL et al (2005) Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. J Int Cancer 117:988–991CrossRef
15.
Zurück zum Zitat Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197PubMedCrossRef Cummings SR, Eckert S, Krueger KA et al (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197PubMedCrossRef
16.
Zurück zum Zitat Cummings SR, Ensrud K, Delmas et al (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362:686–696PubMedCrossRef Cummings SR, Ensrud K, Delmas et al (2010) Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 362:686–696PubMedCrossRef
17.
Zurück zum Zitat Cummings SR, Mcclung M, Reginster JY et al (2011) Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 26:397–404PubMedCrossRef Cummings SR, Mcclung M, Reginster JY et al (2011) Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res 26:397–404PubMedCrossRef
18.
Zurück zum Zitat Curtis MG (2001) Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention. Drug Saf 24:1039–1053PubMedCrossRef Curtis MG (2001) Comparative tolerability of first-generation selective estrogen receptor modulators in breast cancer treatment and prevention. Drug Saf 24:1039–1053PubMedCrossRef
19.
Zurück zum Zitat Cuzick J, Forbes J, Edwards R et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817–824PubMedCrossRef Cuzick J, Forbes J, Edwards R et al (2002) First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360:817–824PubMedCrossRef
20.
Zurück zum Zitat Cuzick J, Forbes JF, Sestak I et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272–282PubMedCrossRef Cuzick J, Forbes JF, Sestak I et al (2007) Long-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 99:272–282PubMedCrossRef
21.
Zurück zum Zitat Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300PubMedCrossRef Cuzick J, Powles T, Veronesi U et al (2003) Overview of the main outcomes in breast-cancer prevention trials. Lancet 361:296–300PubMedCrossRef
22.
Zurück zum Zitat Cuzick J, Sestak I, Forbes JF et al (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383:1041–1048PubMedCrossRef Cuzick J, Sestak I, Forbes JF et al (2014) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383:1041–1048PubMedCrossRef
23.
Zurück zum Zitat Dhingra K (1999) Antiestrogens – tamoxifen, SERMs and beyond. Invest New Drugs 17:285–311PubMedCrossRef Dhingra K (1999) Antiestrogens – tamoxifen, SERMs and beyond. Invest New Drugs 17:285–311PubMedCrossRef
24.
Zurück zum Zitat Domchek SM, Friebel TM, Neuhausen SL et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7:223–229PubMedCrossRef Domchek SM, Friebel TM, Neuhausen SL et al (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 7:223–229PubMedCrossRef
25.
Zurück zum Zitat Domchek SM, Friebel TM, Singer CF et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–975PubMedPubMedCentralCrossRef Domchek SM, Friebel TM, Singer CF et al (2010) Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304:967–975PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Eisen A, Lubinski J, Klijn J et al (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23:7491–7496PubMedCrossRef Eisen A, Lubinski J, Klijn J et al (2005) Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol 23:7491–7496PubMedCrossRef
27.
Zurück zum Zitat Figueiredo JC, Haile RW, Bernstein L et al (2010) Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Res Treat 120:175–183PubMedPubMedCentralCrossRef Figueiredo JC, Haile RW, Bernstein L et al (2010) Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Res Treat 120:175–183PubMedPubMedCentralCrossRef
28.
Zurück zum Zitat Finch A, Beiner M, Lubinski J et al (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296:185–192PubMedCrossRef Finch A, Beiner M, Lubinski J et al (2006) Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 296:185–192PubMedCrossRef
29.
Zurück zum Zitat Finch A, Metcalfe KA, Chiang J et al (2013) The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology 22:212–219PubMedCrossRef Finch A, Metcalfe KA, Chiang J et al (2013) The impact of prophylactic salpingo-oophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology 22:212–219PubMedCrossRef
30.
Zurück zum Zitat Finch A, Metcalfe KA, Chiang JK et al (2011) The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 121:163–168PubMedCrossRef Finch A, Metcalfe KA, Chiang JK et al (2011) The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 121:163–168PubMedCrossRef
31.
Zurück zum Zitat Finch A, Valentini A, Greenblatt E et al (2013) Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril 99:1724–1728PubMedCrossRef Finch A, Valentini A, Greenblatt E et al (2013) Frequency of premature menopause in women who carry a BRCA1 or BRCA2 mutation. Fertil Steril 99:1724–1728PubMedCrossRef
32.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P‑1 study. J Natl Cancer Inst 97:1652–1662PubMedCrossRef Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P‑1 study. J Natl Cancer Inst 97:1652–1662PubMedCrossRef
33.
Zurück zum Zitat Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P‑1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRef Fisher B, Costantino JP, Wickerham DL et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P‑1 Study. J Natl Cancer Inst 90:1371–1388PubMedCrossRef
34.
Zurück zum Zitat Fishman A (2010) The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review. Int J Gynecol Cancer 20:S31–33PubMedCrossRef Fishman A (2010) The effects of parity, breastfeeding, and infertility treatment on the risk of hereditary breast and ovarian cancer: a review. Int J Gynecol Cancer 20:S31–33PubMedCrossRef
35.
Zurück zum Zitat Gallagher JC (2007) Effect of early menopause on bone mineral density and fractures. Menopause 14:567–571PubMedCrossRef Gallagher JC (2007) Effect of early menopause on bone mineral density and fractures. Menopause 14:567–571PubMedCrossRef
36.
Zurück zum Zitat Garcia-Cruz R, Roig I, Robles P et al (2009) ATR, BRCA1 and gammaH2AX localize to unsynapsed chromosomes at the pachytene stage in human oocytes. Reprod Biomed Online 18:37–44PubMedCrossRef Garcia-Cruz R, Roig I, Robles P et al (2009) ATR, BRCA1 and gammaH2AX localize to unsynapsed chromosomes at the pachytene stage in human oocytes. Reprod Biomed Online 18:37–44PubMedCrossRef
37.
Zurück zum Zitat Gierisch JM, Coeytaux RR, Urrutia RP et al (2013) Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 22:1931–1943PubMedCrossRef Gierisch JM, Coeytaux RR, Urrutia RP et al (2013) Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: a systematic review. Cancer Epidemiol Biomarkers Prev 22:1931–1943PubMedCrossRef
38.
Zurück zum Zitat Goss PE, Ingle JN, Ales-Martinez JE et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364:2381–2391PubMedCrossRef Goss PE, Ingle JN, Ales-Martinez JE et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364:2381–2391PubMedCrossRef
39.
Zurück zum Zitat Grady D, Cauley JA, Geiger MJ et al (2008) Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst 100:854–861PubMedPubMedCentralCrossRef Grady D, Cauley JA, Geiger MJ et al (2008) Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk. J Natl Cancer Inst 100:854–861PubMedPubMedCentralCrossRef
40.
Zurück zum Zitat Grenader T, Peretz T, Lifchitz M et al (2005) BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use. Breast 14:264–268PubMedCrossRef Grenader T, Peretz T, Lifchitz M et al (2005) BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use. Breast 14:264–268PubMedCrossRef
41.
Zurück zum Zitat Gronwald J, Byrski T, Huzarski T et al (2006) Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 95:105–109PubMedCrossRef Gronwald J, Byrski T, Huzarski T et al (2006) Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 95:105–109PubMedCrossRef
42.
Zurück zum Zitat Gronwald J, Tung N, Foulkes WD et al (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118:2281–2284PubMedCrossRef Gronwald J, Tung N, Foulkes WD et al (2006) Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer 118:2281–2284PubMedCrossRef
43.
Zurück zum Zitat Haile RW, Thomas DC, Mcguire V et al (2006) BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 15:1863–1870 (a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)PubMedCrossRef Haile RW, Thomas DC, Mcguire V et al (2006) BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. Cancer Epidemiol Biomarkers Prev 15:1863–1870 (a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology)PubMedCrossRef
44.
Zurück zum Zitat Hannaford PC, Selvaraj S, Elliott AM et al (2007) Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner‘s oral contraception study. BMJ 335:651PubMedPubMedCentralCrossRef Hannaford PC, Selvaraj S, Elliott AM et al (2007) Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner‘s oral contraception study. BMJ 335:651PubMedPubMedCentralCrossRef
45.
Zurück zum Zitat Havrilesky LJ, Moorman PG, Lowery WJ et al (2013) Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol 122:139–147PubMedCrossRef Havrilesky LJ, Moorman PG, Lowery WJ et al (2013) Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol 122:139–147PubMedCrossRef
46.
Zurück zum Zitat Iodice S, Barile M, Rotmensz N et al (2010) Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 46:2275–2284PubMedCrossRef Iodice S, Barile M, Rotmensz N et al (2010) Oral contraceptive use and breast or ovarian cancer risk in BRCA1/2 carriers: a meta-analysis. Eur J Cancer 46:2275–2284PubMedCrossRef
47.
Zurück zum Zitat Jernstrom H, Lerman C, Ghadirian P et al (1999) Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354:1846–1850PubMedCrossRef Jernstrom H, Lerman C, Ghadirian P et al (1999) Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 354:1846–1850PubMedCrossRef
48.
Zurück zum Zitat Jernstrom H, Lubinski J, Lynch HT et al (2004) Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96:1094–1098PubMedCrossRef Jernstrom H, Lubinski J, Lynch HT et al (2004) Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 96:1094–1098PubMedCrossRef
49.
Zurück zum Zitat Kauff ND, Barakat RR (2007) Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol 25:2921–2927PubMedCrossRef Kauff ND, Barakat RR (2007) Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol 25:2921–2927PubMedCrossRef
50.
Zurück zum Zitat Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615PubMedCrossRef Kauff ND, Satagopan JM, Robson ME et al (2002) Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346:1609–1615PubMedCrossRef
51.
Zurück zum Zitat Kim J, Oktay K (2013) Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention? Cancer Causes Control 24:421–426PubMedPubMedCentralCrossRef Kim J, Oktay K (2013) Baseline E(2) levels are higher in BRCA2 mutation carriers: a potential target for prevention? Cancer Causes Control 24:421–426PubMedPubMedCentralCrossRef
52.
Zurück zum Zitat Kim J, Skrzynia C, Mersereau JE (2015) A pilot study of BRCA mutation carriers’ knowledge about the clinical impact of prophylactic-oophorectomy and views on fertility consultation: a single-center pilot study. J Genet Couns 24:149–157PubMedCrossRef Kim J, Skrzynia C, Mersereau JE (2015) A pilot study of BRCA mutation carriers’ knowledge about the clinical impact of prophylactic-oophorectomy and views on fertility consultation: a single-center pilot study. J Genet Couns 24:149–157PubMedCrossRef
53.
Zurück zum Zitat King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256PubMedCrossRef King MC, Wieand S, Hale K et al (2001) Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286:2251–2256PubMedCrossRef
54.
Zurück zum Zitat Klip H, Burger CW, Kenemans P et al (2000) Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes Control 11:319–344PubMedCrossRef Klip H, Burger CW, Kenemans P et al (2000) Cancer risk associated with subfertility and ovulation induction: a review. Cancer Causes Control 11:319–344PubMedCrossRef
55.
Zurück zum Zitat Kotsopoulos J, Librach CL, Lubinski J et al (2008) Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control 19:1111–1119PubMedCrossRef Kotsopoulos J, Librach CL, Lubinski J et al (2008) Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study. Cancer Causes Control 19:1111–1119PubMedCrossRef
56.
Zurück zum Zitat Kotsopoulos J, Lubinski J, Gronwald J et al (2015) Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int J Cancer 137:1136–1146PubMedCrossRef Kotsopoulos J, Lubinski J, Gronwald J et al (2015) Factors influencing ovulation and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Int J Cancer 137:1136–1146PubMedCrossRef
57.
Zurück zum Zitat Kotsopoulos J, Lubinski J, Lynch HT et al (2007) Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 105:221–228PubMedCrossRef Kotsopoulos J, Lubinski J, Lynch HT et al (2007) Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 105:221–228PubMedCrossRef
58.
Zurück zum Zitat Kotsopoulos J, Lubinski J, Neuhausen SL et al (2006) Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 100:83–88PubMedCrossRef Kotsopoulos J, Lubinski J, Neuhausen SL et al (2006) Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecol Oncol 100:83–88PubMedCrossRef
59.
Zurück zum Zitat Kotsopoulos J, Lubinski J, Salmena L et al (2012) Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 14:R42PubMedPubMedCentralCrossRef Kotsopoulos J, Lubinski J, Salmena L et al (2012) Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 14:R42PubMedPubMedCentralCrossRef
60.
Zurück zum Zitat Kumle M, Weiderpass E, Braaten T et al (2004) Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women‘s Lifestyle and Health Cohort Study. Br J Cancer 90:1386–1391PubMedPubMedCentralCrossRef Kumle M, Weiderpass E, Braaten T et al (2004) Risk for invasive and borderline epithelial ovarian neoplasias following use of hormonal contraceptives: the Norwegian-Swedish Women‘s Lifestyle and Health Cohort Study. Br J Cancer 90:1386–1391PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Kwiatkowski F, Arbre M, Bidet Y et al (2015) BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk. PLoS ONE 10:e0127363PubMedPubMedCentralCrossRef Kwiatkowski F, Arbre M, Bidet Y et al (2015) BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk. PLoS ONE 10:e0127363PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat Lacroix AZ, Powles T, Osborne CK et al (2010) Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 102:1706–1715PubMedCrossRef Lacroix AZ, Powles T, Osborne CK et al (2010) Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst 102:1706–1715PubMedCrossRef
63.
Zurück zum Zitat Lee E, Ma H, Mckean-Cowdin R et al (2008) Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev 17:3170–3178PubMedCrossRef Lee E, Ma H, Mckean-Cowdin R et al (2008) Effect of reproductive factors and oral contraceptives on breast cancer risk in BRCA1/2 mutation carriers and noncarriers: results from a population-based study. Cancer Epidemiol Biomarkers Prev 17:3170–3178PubMedCrossRef
64.
Zurück zum Zitat Lefkowitz ES, Garland CF (1994) Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol 23:1133–1136PubMedCrossRef Lefkowitz ES, Garland CF (1994) Sunlight, vitamin D, and ovarian cancer mortality rates in US women. Int J Epidemiol 23:1133–1136PubMedCrossRef
65.
Zurück zum Zitat Lin WT, Beattie M, Chen LM et al (2013) Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer 119:1652–1659PubMedPubMedCentralCrossRef Lin WT, Beattie M, Chen LM et al (2013) Comparison of age at natural menopause in BRCA1/2 mutation carriers with a non-clinic-based sample of women in northern California. Cancer 119:1652–1659PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Lindsay R, Hart DM, Forrest C et al (1980) Prevention of spinal osteoporosis in oophorectomised women. Lancet 2:1151–1154PubMedCrossRef Lindsay R, Hart DM, Forrest C et al (1980) Prevention of spinal osteoporosis in oophorectomised women. Lancet 2:1151–1154PubMedCrossRef
67.
Zurück zum Zitat Lippman ME, Cummings SR, Disch DP et al (2006) Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 12:5242–5247PubMedCrossRef Lippman ME, Cummings SR, Disch DP et al (2006) Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Clin Cancer Res 12:5242–5247PubMedCrossRef
68.
Zurück zum Zitat Lokkegaard E, Jovanovic Z, Heitmann BL et al (2006) The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas 53:226–233PubMedCrossRef Lokkegaard E, Jovanovic Z, Heitmann BL et al (2006) The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas 53:226–233PubMedCrossRef
69.
Zurück zum Zitat Ludwig M, Strowitzki T (2010) Prämature Ovarialinsuffizienz. Premature ovarian failure/CME-Fragebogen. Questionnaire. Gynäkologe 43(8):685–695CrossRef Ludwig M, Strowitzki T (2010) Prämature Ovarialinsuffizienz. Premature ovarian failure/CME-Fragebogen. Questionnaire. Gynäkologe 43(8):685–695CrossRef
70.
Zurück zum Zitat Lurie G, Wilkens LR, Thompson PJ et al (2008) Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 19:237–243PubMedCrossRef Lurie G, Wilkens LR, Thompson PJ et al (2008) Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology 19:237–243PubMedCrossRef
71.
Zurück zum Zitat Madalinska JB, Van Beurden M, Bleiker EM et al (2006) The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24:3576–3582PubMedCrossRef Madalinska JB, Van Beurden M, Bleiker EM et al (2006) The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 24:3576–3582PubMedCrossRef
72.
Zurück zum Zitat Mahdavi A, Mahdavi A, Pejovic T et al (2006) Induction of ovulation and ovarian cancer: a critical review of the literature. Fertil Steril 85:819–826PubMedCrossRef Mahdavi A, Mahdavi A, Pejovic T et al (2006) Induction of ovulation and ovarian cancer: a critical review of the literature. Fertil Steril 85:819–826PubMedCrossRef
73.
Zurück zum Zitat Mcguire V, Felberg A, Mills M et al (2004) Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 160:613–618PubMedCrossRef Mcguire V, Felberg A, Mills M et al (2004) Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and noncarriers of BRCA1 gene mutations. Am J Epidemiol 160:613–618PubMedCrossRef
74.
Zurück zum Zitat Mclaughlin JR, Risch HA, Lubinski J et al (2007) Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8:26–34PubMedCrossRef Mclaughlin JR, Risch HA, Lubinski J et al (2007) Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet Oncol 8:26–34PubMedCrossRef
75.
Zurück zum Zitat Melton LJ 3rd, Khosla S, Malkasian GD et al (2003) Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 18:900–905PubMedCrossRef Melton LJ 3rd, Khosla S, Malkasian GD et al (2003) Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 18:900–905PubMedCrossRef
76.
Zurück zum Zitat Metcalfe K, Lynch HT, Ghadirian P et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328–2335PubMedCrossRef Metcalfe K, Lynch HT, Ghadirian P et al (2004) Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 22:2328–2335PubMedCrossRef
77.
Zurück zum Zitat Michaelson-Cohen R, Mor P, Srebnik N et al (2014) BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer 24:233–237PubMedCrossRef Michaelson-Cohen R, Mor P, Srebnik N et al (2014) BRCA mutation carriers do not have compromised ovarian reserve. Int J Gynecol Cancer 24:233–237PubMedCrossRef
78.
Zurück zum Zitat Modan B, Hartge P, Hirsh-Yechezkel G et al (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345:235–240PubMedCrossRef Modan B, Hartge P, Hirsh-Yechezkel G et al (2001) Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 345:235–240PubMedCrossRef
79.
Zurück zum Zitat Moorman PG, Havrilesky LJ, Gierisch JM et al (2013) Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 31:4188–4198PubMedCrossRef Moorman PG, Havrilesky LJ, Gierisch JM et al (2013) Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol 31:4188–4198PubMedCrossRef
80.
Zurück zum Zitat Moslehi R, Singh R, Lessner L et al (2010) Impact of BRCA mutations on female fertility and offspring sex ratio. Am J Hum Biol 22:201–205PubMedPubMedCentral Moslehi R, Singh R, Lessner L et al (2010) Impact of BRCA mutations on female fertility and offspring sex ratio. Am J Hum Biol 22:201–205PubMedPubMedCentral
81.
Zurück zum Zitat Murphy GJ, Holder JC (2000) PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21:469–474PubMedCrossRef Murphy GJ, Holder JC (2000) PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 21:469–474PubMedCrossRef
82.
83.
Zurück zum Zitat Narod SA, Brunet JS, Ghadirian P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876–1881PubMedCrossRef Narod SA, Brunet JS, Ghadirian P et al (2000) Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356:1876–1881PubMedCrossRef
84.
Zurück zum Zitat Nelson HD, Pappas M, Zakher B et al (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 160:255–266PubMedCrossRef Nelson HD, Pappas M, Zakher B et al (2014) Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med 160:255–266PubMedCrossRef
85.
Zurück zum Zitat Oktay K, Kim JY, Barad D et al (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 28:240–244PubMedPubMedCentralCrossRef Oktay K, Kim JY, Barad D et al (2010) Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks. J Clin Oncol 28:240–244PubMedPubMedCentralCrossRef
86.
Zurück zum Zitat Pal T, Keefe D, Sun P et al (2010) Fertility in women with BRCA mutations: a case-control study. Fertil Steril 93:1805–1808PubMedCrossRef Pal T, Keefe D, Sun P et al (2010) Fertility in women with BRCA mutations: a case-control study. Fertil Steril 93:1805–1808PubMedCrossRef
87.
Zurück zum Zitat Perri T, Lifshitz D, Sadetzki S et al (2015) Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertil Steril 103:1305–1312PubMedCrossRef Perri T, Lifshitz D, Sadetzki S et al (2015) Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers. Fertil Steril 103:1305–1312PubMedCrossRef
88.
Zurück zum Zitat Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98–101PubMedCrossRef Powles T, Eeles R, Ashley S et al (1998) Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98–101PubMedCrossRef
89.
Zurück zum Zitat Powles TJ, Ashley S, Tidy A et al (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283–290PubMedCrossRef Powles TJ, Ashley S, Tidy A et al (2007) Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst 99:283–290PubMedCrossRef
90.
Zurück zum Zitat Rebbeck TR, Friebel T, Wagner T et al (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804–7810PubMedCrossRef Rebbeck TR, Friebel T, Wagner T et al (2005) Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 23:7804–7810PubMedCrossRef
91.
Zurück zum Zitat Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622PubMedCrossRef Rebbeck TR, Lynch HT, Neuhausen SL et al (2002) Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346:1616–1622PubMedCrossRef
92.
Zurück zum Zitat Reitsma W, De Bock GH, Oosterwijk JC et al (2013) Support of the “fallopian tube hypothesis” in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 49:132–141PubMedCrossRef Reitsma W, De Bock GH, Oosterwijk JC et al (2013) Support of the “fallopian tube hypothesis” in a prospective series of risk-reducing salpingo-oophorectomy specimens. Eur J Cancer 49:132–141PubMedCrossRef
93.
Zurück zum Zitat Rhiem K, Foth D, Wappenschmidt B et al (2011) Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 283:623–627PubMedCrossRef Rhiem K, Foth D, Wappenschmidt B et al (2011) Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Arch Gynecol Obstet 283:623–627PubMedCrossRef
94.
95.
Zurück zum Zitat Rutter JL, Wacholder S, Chetrit A et al (2003) Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 95:1072–1078PubMedCrossRef Rutter JL, Wacholder S, Chetrit A et al (2003) Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst 95:1072–1078PubMedCrossRef
96.
Zurück zum Zitat Salhab M, Sarakbi AW, Mokbel K (2005) In vitro fertilization and breast cancer risk: a review. Int J Fertil Womens Med 50:259–266PubMed Salhab M, Sarakbi AW, Mokbel K (2005) In vitro fertilization and breast cancer risk: a review. Int J Fertil Womens Med 50:259–266PubMed
97.
Zurück zum Zitat Sharan SK, Pyle A, Coppola V et al (2004) BRCA2 deficiency in mice leads to meiotic impairment and infertility. Development 131:131–142PubMedCrossRef Sharan SK, Pyle A, Coppola V et al (2004) BRCA2 deficiency in mice leads to meiotic impairment and infertility. Development 131:131–142PubMedCrossRef
98.
Zurück zum Zitat Sherwin BB, Gelfand MM (1987) The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 49:397–409PubMedCrossRef Sherwin BB, Gelfand MM (1987) The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 49:397–409PubMedCrossRef
99.
Zurück zum Zitat Shifren JL (2002) Androgen deficiency in the oophorectomized woman. Fertil Steril 77(Suppl 4):S60–S62PubMedCrossRef Shifren JL (2002) Androgen deficiency in the oophorectomized woman. Fertil Steril 77(Suppl 4):S60–S62PubMedCrossRef
100.
Zurück zum Zitat Shifren JL, Braunstein GD, Simon JA et al (2000) Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343:682–688PubMedCrossRef Shifren JL, Braunstein GD, Simon JA et al (2000) Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 343:682–688PubMedCrossRef
101.
Zurück zum Zitat Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90:1529–1536PubMedCrossRef Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90:1529–1536PubMedCrossRef
102.
Zurück zum Zitat Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 90:1609–1620PubMedCrossRef Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J Natl Cancer Inst 90:1609–1620PubMedCrossRef
103.
Zurück zum Zitat Tinelli A, Malvasi A, Leo G et al (2010) Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal. Cancer Metastasis Rev 29:339–350PubMedCrossRef Tinelli A, Malvasi A, Leo G et al (2010) Hereditary ovarian cancers: from BRCA mutations to clinical management. A modern appraisal. Cancer Metastasis Rev 29:339–350PubMedCrossRef
104.
Zurück zum Zitat Titus S, Li F, Stobezki R et al (2013) Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 5:172ra121CrossRef Titus S, Li F, Stobezki R et al (2013) Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans. Sci Transl Med 5:172ra121CrossRef
105.
Zurück zum Zitat Uray IP, Brown PH (2011) Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent results in cancer research. Fortschritte der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer 188:147–162PubMedPubMedCentral Uray IP, Brown PH (2011) Chemoprevention of hormone receptor-negative breast cancer: new approaches needed. Recent results in cancer research. Fortschritte der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer 188:147–162PubMedPubMedCentral
106.
Zurück zum Zitat Valentini A, Lubinski J, Byrski T et al (2013) The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat 142:177–185PubMedPubMedCentralCrossRef Valentini A, Lubinski J, Byrski T et al (2013) The impact of pregnancy on breast cancer survival in women who carry a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat 142:177–185PubMedPubMedCentralCrossRef
107.
Zurück zum Zitat Venn A, Healy D, Mclachlan R (2003) Cancer risks associated with the diagnosis of infertility. Best Pract Res Clin Obstet Gynaecol 17:343–367PubMedCrossRef Venn A, Healy D, Mclachlan R (2003) Cancer risks associated with the diagnosis of infertility. Best Pract Res Clin Obstet Gynaecol 17:343–367PubMedCrossRef
108.
Zurück zum Zitat Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93–97PubMedCrossRef Veronesi U, Maisonneuve P, Costa A et al (1998) Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Lancet 352:93–97PubMedCrossRef
109.
Zurück zum Zitat Veronesi U, Maisonneuve P, Rotmensz N et al (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99:727–737PubMedCrossRef Veronesi U, Maisonneuve P, Rotmensz N et al (2007) Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst 99:727–737PubMedCrossRef
110.
Zurück zum Zitat Veronesi U, Mariani L, Decensi A et al (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17:1065–1071PubMedCrossRef Veronesi U, Mariani L, Decensi A et al (2006) Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. Ann Oncol 17:1065–1071PubMedCrossRef
111.
112.
Zurück zum Zitat Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P‑2 trial. JAMA 295:2727–2741PubMedCrossRef Vogel VG, Costantino JP, Wickerham DL et al (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P‑2 trial. JAMA 295:2727–2741PubMedCrossRef
113.
Zurück zum Zitat Vogel VG, Costantino JP, Wickerham DL et al (2010) Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P‑2 Trial: preventing breast cancer. Cancer Prev Res (Phila Pa) 3:696–706CrossRef Vogel VG, Costantino JP, Wickerham DL et al (2010) Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P‑2 Trial: preventing breast cancer. Cancer Prev Res (Phila Pa) 3:696–706CrossRef
114.
Zurück zum Zitat Walker JL, Powell CB, Chen LM et al (2015) Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 121(13):2108–2120PubMedCrossRef Walker JL, Powell CB, Chen LM et al (2015) Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 121(13):2108–2120PubMedCrossRef
115.
Zurück zum Zitat Wassertheil-Smoller S, Hendrix SL, Limacher M et al (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 289:2673–2684PubMedCrossRef Wassertheil-Smoller S, Hendrix SL, Limacher M et al (2003) Effect of estrogen plus progestin on stroke in postmenopausal women: the Women’s Health Initiative: a randomized trial. JAMA 289:2673–2684PubMedCrossRef
116.
Zurück zum Zitat Williams CJ, Simera I, Bryant A (2010) Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev :CD001034. DOI: 10.1002/14651858.CD001034.pub2.PubMed Williams CJ, Simera I, Bryant A (2010) Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev :CD001034. DOI: 10.1002/14651858.CD001034.pub2.PubMed
117.
Zurück zum Zitat Zhu H, Lei X, Feng J et al (2012) Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies. Eur J Contracept Reproductive Health Care 17:402–414CrossRef Zhu H, Lei X, Feng J et al (2012) Oral contraceptive use and risk of breast cancer: a meta-analysis of prospective cohort studies. Eur J Contracept Reproductive Health Care 17:402–414CrossRef
Metadaten
Titel
Endocrine interventions in women with BRCA1/2 mutations
A systematic review
verfasst von
Dr. Susanne Schüler-Toprak
PD Dr. Stephan Seitz
Prof. Dr. Olaf Ortmann
Publikationsdatum
01.05.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Die Gynäkologie / Ausgabe 5/2016
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI
https://doi.org/10.1007/s00129-016-3864-7

Weitere Artikel der Ausgabe 5/2016

Der Gynäkologe 5/2016 Zur Ausgabe

Einführung zum Thema

Das Zervixkarzinom

Magazin

Magazin

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.